TVTX · Insider Trading
Travere Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by TVTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | MIXED | — | −$205.01K |
| 2026-09-17 | Elizabeth E Reed | Chief Legal Officer and GC | MIXED | — | −$1.76M |
| 2026-09-17 | Jula Inrig | EVP, Head of R&D & CMO | MIXED | −12,279 | −$2.50M |
| 2026-09-17 | Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | MIXED | −25,000 | −$13.81M |
| 2026-09-17 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | MIXED | −30,508 | −$2.80M |
| 2026-09-17 | William E. Rote | Chief Research Officer | MIXED | −17,548 | −$9.04M |
| 2026-09-17 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | −$16.05M |
| 2026-09-11 | Jeffrey A Meckler | Director | MIXED | — | −$906.51K |
| 2026-09-03 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sell | −642 | −$42.61K |
| 2026-08-19 | Gary A Lyons | Director | MIXED | — | −$458.45K |
| 2026-06-22 | Jula Inrig | CHIEF MEDICAL OFFICER | G | −468 | — |
| 2026-06-16 | Timothy Coughlin | Director | MIXED | — | −$235.55K |
| 2026-06-16 | Roy D. Baynes | Director | MIXED | — | −$128.79K |
| 2026-05-21 | John A Orwin | Director | A | +4,000 | — |
| 2026-05-21 | Gary A Lyons | Director | A | +4,000 | — |
| 2026-05-21 | Brinkley Ruth Williams | Director | A | +4,000 | — |
| 2026-05-21 | Jeffrey A Meckler | Director | A | +4,000 | — |
| 2026-05-21 | Sandra Poole | Director | A | +4,000 | — |
| 2026-05-21 | Timothy Coughlin | Director | A | +4,000 | — |
| 2026-05-21 | Roy D. Baynes | Director | A | +4,000 | — |
| 2026-05-21 | Suzanne Louise Bruhn | Director | A | +4,000 | — |
| 2026-05-21 | Ron Squarer | Director | A | +4,000 | — |
| 2026-05-19 | Timothy Coughlin | Director | Sell | −3,250 | −$141.34K |
| 2026-05-06 | Jeffrey A Meckler | Director | MIXED | — | −$229.36K |
| 2026-05-06 | Peter Heerma | CHIEF COMMERCIAL OFFICER | MIXED | +2,076 | −$101.42K |
| 2026-05-06 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | MIXED | +1,759 | −$115.37K |
| 2026-05-06 | Jula Inrig | CHIEF MEDICAL OFFICER | MIXED | +1,765 | −$567.09K |
| 2026-05-06 | William E. Rote | Chief Research Officer | MIXED | +1,487 | −$121.43K |
| 2026-05-06 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | −$988.88K |
| 2026-05-06 | Elizabeth E Reed | Chief Legal Officer and GC | MIXED | — | −$733.46K |
| 2026-05-06 | Roy D. Baynes | Director | MIXED | — | −$127.71K |
| 2026-05-04 | Roy D. Baynes | Director | MIXED | — | −$364.65K |
| 2026-04-23 | William E. Rote | Chief Research Officer | Sell | −9,100 | −$355.72K |
| 2026-04-16 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | MIXED | −6,727 | −$657.79K |
| 2026-04-16 | Gary A Lyons | Director | MIXED | — | −$197.92K |
| 2026-04-16 | Roy D. Baynes | Director | MIXED | — | −$775.82K |
| 2026-04-15 | Jula Inrig | CHIEF MEDICAL OFFICER | MIXED | +5,767 | −$345.89K |
| 2026-04-15 | William E. Rote | Chief Research Officer | A | +14,000 | — |
| 2026-04-15 | Peter Heerma | CHIEF COMMERCIAL OFFICER | MIXED | +6,785 | −$302.52K |
| 2026-04-15 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | −$2.63M |
| 2026-04-15 | Elizabeth E Reed | Chief Legal Officer and GC | MIXED | — | −$1.46M |
| 2026-04-15 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | MIXED | +5,673 | −$348.97K |
| 2026-04-07 | Roy D. Baynes | Director | MIXED | — | −$64.80K |
| 2026-04-02 | Elizabeth E Reed | Chief Legal Officer and GC | MIXED | — | −$145.40K |
| 2026-04-02 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | −$928.24K |
| 2026-03-18 | Elizabeth E Reed | Chief Legal Officer and GC | MIXED | — | −$90.06K |
| 2026-02-24 | Eric M Dube | CHIEF EXECUTIVE OFFICER | MIXED | — | −$878.17K |
| 2026-02-19 | Elizabeth E Reed | Chief Legal Officer and GC | MIXED | — | −$87.52K |
| 2026-02-05 | Jula Inrig | CHIEF MEDICAL OFFICER | Sell | −1,779 | −$57.30K |
| 2026-02-05 | Elizabeth E Reed | Chief Legal Officer and GC | Sell | −2,994 | −$96.36K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Eric M Dube | CHIEF EXECUTIVE OFFICER | 465,054 | $23.07M |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | 289,783 | $14.37M |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | 138,016 | $6.85M |
| Elizabeth E Reed | Chief Legal Officer and GC | 105,689 | $5.24M |
| Jeffrey A Meckler | Director | 101,500 | $5.03M |
| Jula Inrig | EVP, Head of R&D & CMO | 100,891 | $5.00M |
| William E. Rote | Chief Research Officer | 98,547 | $4.89M |
| Timothy Coughlin | Director | 66,250 | $3.29M |
| Gary A Lyons | Director | 62,400 | $3.10M |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 44,853 | $2.22M |
| Roy D. Baynes | Director | 41,500 | $2.06M |
| Ron Squarer | Director | 39,375 | $1.95M |
| John A Orwin | Director | 39,375 | $1.95M |
| Sandra Poole | Director | 34,000 | $1.69M |
| Suzanne Louise Bruhn | Director | 32,750 | $1.62M |
| Brinkley Ruth Williams | Director | 29,750 | $1.48M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TVTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.